bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.51 USD
+0.01 (2.28%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $0.51 0.00 (0.79%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth A Momentum C VGM
Zacks News
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma
by Zacks Equity Research
AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.
Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea
by Zacks Equity Research
Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.
Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Celgene (CELG) Q4 earnings beat estimates on robust revenues, driven by strong sales of Otezla and Revlimid.
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
5 Best Biotech Bets Likely to Outperform Estimates in Q4
by Zacks Equity Research
Let us take a look at five promising biotech stocks for the fourth quarter of 2018.
Celgene (CELG) Provides Guidance for 2019, Updates Pipeline
by Zacks Equity Research
Celgene (CELG) announces guidance for 2019, and other pipeline and regulatory updates.
Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus
by Sweta Killa
The news has put the spotlight on a number of healthcare ETFs, especially biotech and pharma, which could be the best ways for investors to tap the opportunity arising from the BMY-CELG deal.
Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China
by Zacks Equity Research
This week, focus was on data presented at the annual conference of the American Society of Hematology from Dec 1-4. Apart from this, the regular pipeline updates were also in focus in the biotech sector.
Global Blood Therapeutics' Voxelotor on Faster Approval Path
by Zacks Equity Research
Global Blood Therapeutics (GBT) announces FDA nod for an accelerated approval pathway for voxelotor as a treatment for sickle cell disease. Stock rallies.
Celgene (CELG) Announces Various Cancer Data at ASH 2018
by Zacks Equity Research
Celegne (CELG) presents data from several cancer studies at the annual meeting of American Society of Hematology (ASH).
Bluebird (BLUE) Down 5.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Celgene & Bluebird's CAR T Therapy Study Completes Enrollment
by Zacks Equity Research
Celgene (CELG) and partner bluebird complete enrollment in a phase II study for CAR T cell therapy candidate, bb2121 for patients with relapsed and refractory multiple myeloma.
Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News
by Zacks Equity Research
Pipeline and regulatory updates are the key highlights in the biotech sector this week.
Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Regeneron (REGN) Q3 results beat on earnings, while sales meet expectations. However, the company's dependence on Eylea to boost revenues is a concern.
bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.
Bluebird Bio (BLUE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Bluebird (BLUE) delivered earnings and revenue surprises of 5.21% and 39.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Is a Disappointment in Store for bluebird (BLUE) Q3 Earnings?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when bluebird (BLUE) reports third-quarter results.
Analysts Estimate Bluebird Bio (BLUE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celgene (CELG) Tops Q3 Earnings & Sales Estimates, Ups View
by Zacks Equity Research
Celgene (CELG) third-quarter revenues gain on strong sales of Otezla and Revlimid.
Celgene's Otezla Meets Goal in Scalp Plaque Psoriasis Study
by Zacks Equity Research
Celgene's (CELG) efforts to expand psoriasis drug, Otezla gets a boost as the late-stage study for the indication of plaque psoriasis of the scalp meets primary endpoint.
Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy
by Neena Mishra
2018 Nobel Prize for medicine was awarded for immunotherapy research. Here is what investors need to know about stocks and ETF focused on this innovative area.
bluebird's MAA for LentiGlobin Gene Therapy Accepted by EMA
by Zacks Equity Research
bluebird's marketing authorization application (MAA) for its experimental gene therapy, LentiGlobin, was accepted by the regulatory body in Europe.
Upcoming Earnings to Watch: KR, PLAY, TLRD
by Ryan McQueeney
Will any of the earnings reports coming in the next few days have enough positive news to outweigh other headwinds? Let's take a closer look.
bluebird (BLUE) Reports Updated Data on Lenti-D Gene Therapy
by Zacks Equity Research
bluebird bio (BLUE) announces updated results from phase II/III Starbeam study of its Lenti-D gene therapy in boys aged 17 years or below with CALD.